Summary of Ascendis Pharma (ASND) Conference Call Company and Industry Overview - **Company**: Ascendis Pharma - **Industry**: Biotechnology, specifically focusing on treatments for growth disorders such as achondroplasia Key Findings from the COAST Trial - The COAST trial is a Phase II study assessing the efficacy of a combination therapy involving TransCon CNP and TransCon Growth Hormone in children with achondroplasia aged 2 to 11 years [2][3] - The trial reported a significant increase in annualized growth velocity (AGV) for treatment-naive children, achieving 9.14 cm/year, which is an increase of 4.2 cm/year compared to baseline [19][20] - For children previously treated with TransCon CNP, the AGV was 8.25 cm/year, reflecting a 3.1 cm/year increase from baseline [21][22] Efficacy and Safety Data - The combination therapy demonstrated a 0.53 increase in height Z score for treatment-naive patients and a 0.44 increase for treatment-experienced patients after 26 weeks [20][22] - The safety profile of the combination therapy was comparable to that of the individual therapies, with no serious adverse events related to the study drug reported [17][18] - The combination therapy resulted in a linear growth improvement associated with better body proportionality, which is crucial for children with achondroplasia [24][25] Future Development Plans - Ascendis Pharma plans to initiate a Phase III trial by the end of 2025, which will include both treatment-naive and experienced children [26][30] - The company aims to expand its treatment options for growth disorders and explore over 20 potential indications for its therapies [27][84] Market Position and Strategy - Ascendis Pharma is positioned as a leader in the growth disorder treatment market, with a focus on developing unique treatment combinations that unlock new therapeutic potentials [27][84] - The company is considering co-formulating TransCon CNP and TransCon Growth Hormone into a single injection for improved patient compliance [45][103] Additional Insights - The trial results indicate a potential for achieving catch-up growth in children with achondroplasia, which could normalize their height relative to parental expectations [80] - The combination therapy is expected to provide significant benefits beyond linear growth, addressing broader health concerns associated with achondroplasia [81][96] Conclusion - Ascendis Pharma's recent trial results highlight a promising advancement in the treatment of achondroplasia, with significant improvements in growth velocity and safety. The company is poised to expand its market presence and explore additional indications for its therapies, reinforcing its commitment to addressing growth disorders effectively.

Core Insights - Ascendis Pharma announced positive interim results from the COACH Trial, demonstrating that the combination of TransCon CNP and TransCon hGH significantly improves growth and body proportionality in children with achondroplasia after 26 weeks of treatment [2][4][12] Group 1: Clinical Trial Results - For treatment-naïve children, the combination treatment resulted in a mean annualized growth velocity (AGV) of 9.14 cm/year, with a height Z-score improvement of +0.53 over 26 weeks [1][12] - For children previously treated with TransCon CNP, the mean AGV was 8.25 cm/year, with a height Z-score improvement of +0.44 over the same period [1][12] - The combination treatment led to accelerated improvement in body proportionality, aligning with increased linear growth [1][12] Group 2: Safety and Tolerability - The safety and tolerability profile of the combination treatment was consistent with that of the individual monotherapies, with generally mild treatment-emergent adverse events (TEAEs) reported [1][4][12] Group 3: Trial Design and Future Plans - The COACH Trial is a Phase 2 open-label trial investigating the efficacy, safety, and tolerability of the combination treatment in children aged 2 to 11 years with achondroplasia [5] - The interim analysis will be followed by Week 52 data, expected in Q4 2025, with plans to initiate a Phase 3 trial in the same timeframe [5][11] Group 4: Product Information - TransCon CNP is under priority review by the FDA as a monotherapy for children with achondroplasia, while TransCon hGH is already approved and marketed as SKYTROFA for pediatric growth hormone deficiency [3][10] - Both products utilize Ascendis Pharma's innovative TransCon technology platform, which aims to provide sustained release of active compounds [3][10]

Core Insights - Markel Insurance has appointed Sucheng Chang as the new Managing Director for Asia Pacific, effective July 14, 2025 [1][2] - Chang will lead Markel International's Asia Pacific business, focusing on profitable growth and exceptional client service [2][4] - The Asia Pacific business has seen a 600% increase in Gross Written Premium (GWP) since 2019, with underwriting profitability improving and employee numbers rising by nearly 300% [3] Company Strategy - The Accelerate Asia Pacific strategy is central to Markel International's growth agenda, aiming to build on the momentum achieved in the region [4] - Chang's leadership is expected to enhance the company's presence in the US$300 billion GWP Asia-Pacific insurance market [4][3] Leadership Background - Sucheng Chang has extensive experience in scaling insurance operations in Asia, previously serving as CEO for Aon in Hong Kong and holding strategic roles at Liberty Mutual for over 13 years [4][3] - Chang holds an MBA from Yale University and a BA from Boston University, indicating a strong educational background [4]

Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Europe Rice Noodles Market, By Country, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering. The Europe Rice Noodles Market was valued at USD 2.18 Billion in 2024 and is expected to reach USD 3.86 Billion by 2030, rising at a CAGR of 9.99%. The market is witnessing sustained growth as European consumers increasingly turn to gluten-free and health-conscious dietary options. The popularity of Asian cuisine acros ...

Former buy-side equity analyst covering Asia Pacific equities with a decade of experience under my belt. I employ a fundamental bottom-up approach with a macroeconomic overlay to identify stocks that are set to benefit from broader trends globally. I focus mainly on Financials, Industrials and Consumer Discretionary sectors. I started writing on Seeking Alpha to share my thoughts and shine a light on Asian equities listed in US markets. Asian equities (ex-China) are often times overlooked and under-allocate ...

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (cr ...

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtal ...

13 May 2025 | 6:25PM SGT Global Markets Daily: Asian FX — What's Changed, What's Not, and Where Next From Here? (Suwanapruti) Asian FX — What's Changed, What's Not, and Where Next From Here? On Monday, 12 May, the Trump administration announced a 90-day pause in retaliatory tariffs imposed on Chinese imports in April, which will leave the US tariff increases at +30pp (from +145pp, previously). Likewise, China also reduced its retaliatory tariff on US imports to +10pp (from +125pp, previously). While we expe ...

May 8, 2025 06:43 AM GMT 亚洲经济研究 | Asia Pacific M Idea 观点：油价下跌⸺亚洲受益 程度有多大？ 油价下跌将减轻亚洲的石油负担，并可能对增长产生一定的 抵消作用。尽管如此，贸易紧张局势仍将是一个巨大的拖 累。油价疲软和货币走强的局面如果持续下去，可能会导致 降息幅度超出我们目前的预期。 要点 在本报告中，我们详细介绍了CPI通胀和经常账户余额对油价下跌的敏感性。 Exhibit 1: 亚洲是比美国和欧元区更大 的石油净进口地区 -2.4% 0.02% -1.8% -4.0% -3.5% -3.0% -2.5% -2.0% -1.5% -1.0% -0.5% 0.0% 0.5% Mar-13 Mar-15 Mar-17 Mar-19 Mar-21 Mar-23 Mar-25 Oil and gas trade balance (% of GDP, 12M trailing sum) Asia US EA 资料来源：Haver、摩根士丹利研究部 益 Exhibit 2: 泰国、韩国、台湾地区、印 度和日本相对而言受益更多，而马来西 亚和澳大利亚这两个净出口国则没有 ...

Rallybio Corporation (RLYB) 2025 Conference May 07, 2025 12:00 PM ET Speaker0 BUCELL actually had like a commentary in New England Journal like last week or two weeks ago, which is interesting. Speaker1 I didn't see that on FNAIT or Yeah. I'll have to dig one out. I would say it's bit of a bad memory at the moment, so it's still post traumatic stress. Speaker0 Good afternoon, I guess, everybody. John Wallabin, senior analyst here at Citizens, and welcome to day one of our Life Sciences Conference. Pleased t ...